Last reviewed · How we verify
placebo + avastin + platinum-based chemotherapy
This combination uses platinum-based chemotherapy to damage cancer cell DNA while bevacizumab (Avastin) blocks tumor blood vessel formation, with placebo as a control arm.
This combination uses platinum-based chemotherapy to damage cancer cell DNA while bevacizumab (Avastin) blocks tumor blood vessel formation, with placebo as a control arm. Used for Ovarian cancer (likely, given ARCAGY/GINECO GROUP focus on gynecologic malignancies).
At a glance
| Generic name | placebo + avastin + platinum-based chemotherapy |
|---|---|
| Sponsor | ARCAGY/ GINECO GROUP |
| Drug class | Combination therapy: platinum-based chemotherapy + anti-angiogenic monoclonal antibody |
| Target | DNA (platinum agents); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Platinum agents (e.g., cisplatin, carboplatin) create DNA crosslinks to kill rapidly dividing cancer cells. Bevacizumab is a monoclonal antibody targeting VEGF (vascular endothelial growth factor), which inhibits angiogenesis and starves tumors of blood supply. The placebo arm allows comparison of the active combination's efficacy in this Phase 3 trial.
Approved indications
- Ovarian cancer (likely, given ARCAGY/GINECO GROUP focus on gynecologic malignancies)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy
- Hypertension
- Proteinuria
- Bleeding/thromboembolic events
Key clinical trials
- Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) (PHASE3)
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (PHASE3)
- A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (PHASE3)
- A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer (PHASE3)
- ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (PHASE3)
- Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (PHASE3)
- A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer (PHASE2, PHASE3)
- A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: